Clinical Trial Update: A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus [Phase 3]

View source ↗

Summary

The Phase 3 trial of tabalumab (LY2127399) for systemic lupus erythematosus, using two injection methods, was terminated. Results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Tabalumab (tabalumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Lupus Erythematosus, Systemic | Phase 3 | Status: TERMINATED | Results posted: 2018-06-15